Recro Pharma to Lay Off 50 Following Second FDA Rejection for Non-Opioid Pain Treatment

Malvern, Penn.-based Recro Pharma will terminate approximately 50 employees of its Acute Care Segment. The cuts came less than two weeks after the company received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its non-opioid pain medication, IV meloxicam.